The United Kingdom

Alexion Mission

Pioneering New Possibilities for the Rare Disease Community

We are driven by a mission to change what it means to live with a rare disease. Built on a legacy of turning pioneering science into transformative treatments, we listen to and partner with the rare disease ecosystem to help improve outcomes for more people impacted by rare diseases across the globe.

Developing breakthrough therapies for rare diseases is only possible because of the tireless efforts of our global community of researchers and scientists, advocates and caregivers, and most important, patients.

As part of AstraZeneca, we have the potential to impact the lives of even more people around the world.

Alexion in the United Kingdom

Alexion’s UK office was one of the first affiliates to open outside of the US, in 2006, to serve patients across the UK and also the Republic of Ireland. Operating from London and with teams across the UK and Ireland, we work hard every day to bring about positive change for the rare disease community.

As well as bringing innovative new therapies to patients, we work collaboratively within the rare disease ecosystem to find ways to accelerate time to diagnosis, create access to innovative treatments, and work collaboratively with the NHS to support the delivery of specialised services.

*Alexion UK encompasses all commercial operations across the UK and Republic of Ireland.

Paroxysmal Nocturnal Haemoglobinuria (PNH)

A rare, chronic, progressive and potentially life-threatening blood disorder. It is characterised by red blood cell destruction within blood vessels (also known as intravascular haemolysis) and white blood cell and platelet activation, which can result in thrombosis (blood clots).

Atypical Haemolytic Uraemic Syndrome (aHUS)

A rare disease that can cause progressive injury to vital organs, primarily the kidneys, via damage to the walls of blood vessels and blood clots.

Neurofibromatosis Type 1 (NF1) Plexiform Neurofibromas (PN)

A rare, progressive, genetic condition characterized by non-malignant (non-cancerous) tumors called plexiform neurofibromas (PN) that develop in the brain, and along the spinal cord and nerve.

Generalised Myasthenia Gravis (gMG)

A rare, autoimmune neuromuscular disease characterised by loss of muscle function and severe muscle weakness.

Neuromyelitis Optica Spectrum Disorder (NMOSD)

A rare autoimmune disease of the central nervous system, characterised by unpredictable relapses which can result in cumulative disability.

Hypophosphatasia (HPP)

A rare, inherited, metabolic disease characterized by impaired mineralization (“calcification”), the process that hardens and strengthens bones and teeth. This can lead to poor growth and development, weakness and deformity of bones and other skeletal abnormalities, and premature loss of teeth with the root intact.

Lysosomal Acid Lipase Deficiency (LAL-D)

A genetic, and progressive ultra-rare metabolic disease associated with multiorgan damage in infant, paediatric and adult patients, and premature death in infants.

Medicines

Medicines Licensed in the UK

For information on medicines licensed in the UK please click here.

Clinical Trials

Alexion is committed to serving people affected by rare diseases through the discovery, development and delivery of life-changing medicines. Our goal is to bring safe and effective medicines to as many patients as possible by conducting rigorous clinical trials and obtaining marketing approval by regulatory authorities around the world. Our work is marked by a commitment to the highest standards of preclinical and clinical research, and an acute sense of urgency. As such, we prioritize access to our investigational medicines through participation in a clinical trial.

Contact us

Transparency and Disclosure

Alexion is committed to operating with integrity, accountability, and transparency, and to complying with all applicable laws and regulations. Alexion fully participates in the Association of British Pharmaceutical Industry’s (ABPI) Disclosure UK initiative, to increase transparency about the relationships we have with doctors, nurses, pharmacists, and other healthcare professionals.

Disclosure

Working with Patient Groups

People living with rare diseases are our inspiration and our Guiding Star. Every day we strive to live up to their expectations by following our culture values to put patients first, do the right thing, follow the science, be entrepreneurial, and play to win.

Alexion respects the independence and integrity of patient organisations. We declare any support provided to patient groups to ensure transparency of our partnerships. View the contributions we have made to patient organisations.

Working with Members of the Public

At Alexion, we foster an environment that attracts and retains the best talent. We provide the tools to enable each individual to perform at their personal best so that we maximize our collective impact.

Career Opportunities

Uniting our teams driven by our commitment to pioneer life-changing outcomes for the rare disease community and the health systems we operate in.

At Alexion, we foster an environment that attracts and retains the best talent.

Explore Careers

Alexion Pharma UK Ltd

Customer Operations - Customer Order queries

6th Floor
2 Pancras Square London,
N1C 4AG

UK 0800 1300 212

Veeva ID: M/UK/UNB-U/0495

Date of Preparation: March 2026

Alexion UK Page

Research and Development

Innovation

Therapy Areas